Chat
Nicotine and Metabolites, Serum or Plasma, Quantitative
Copy Utility
Use to detect and monitor nicotine, cotinine, and trans-3'-hydroxycotinine in serum or plasma. Serum or plasma testing may be useful when a valid urine specimen cannot be obtained (anuretic or dialysis).
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Sun-Sat
1-4 days
Plain red, green (sodium heparin), lavender (EDTA), pink (K2EDTA), or SST.
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL)
Refrigerated.
Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years
Effective August 17, 2015
| Drugs Covered | Cutoff Concentrations |
| Nicotine | 2 ng/mL |
| Cotinine (metabolite) | 2 ng/mL |
| 3-OH-Cotinine (metabolite) | 2 ng/mL |
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Positive cutoff: 2 ng/mL
For medical purposes only; not valid for forensic use.
This test is designed to evaluate recent use of nicotine-containing products. Passive and active exposure cannot be discriminated definitively, although a cutoff of 10 ng/mL cotinine is frequently used for surgery qualification purposes. For smoking cessation programs or compliance testing, the absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. This test cannot distinguish between use of tobacco and purified nicotine products. The concentration value must be greater than or equal to the cutoff to be reported as positive.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
80323 (Alt code: G0480)
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0092362 | Nicotine, S/P, Quant | 3853-9 |
| 0092363 | Cotinine, S/P, Quant | 10365-5 |
| 0092364 | 3-OH-Cotinine, S/P, Quant | 35140-3 |
- 3-Hydroxycotinine
- Cotinine
- Nicotine
- Nicotine and Cotinine, LC/MS/MS, Serum/Plasma
- Pain Management
Feedback
